FDA Nod For NVO's Hemophilia A Drug, ICPT's NASH Trial Hits Goal, NVTA Abuzz

Today's Daily Dose brings you news about Bausch Health's acquisition of the U.S. rights to Eton Pharma's EM-100 eye drop; Cellular Biomedicine's business highlights and financial results for Q4, 2018; CE Mark approval for Edwards Lifesciences' PASCAL transcatheter valve repair system; Invitae's better-than-expected Q4 financial results among others.

from RTT - Biotech https://ift.tt/2DUes6K
via IFTTT